Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10493042
ABSTRACT:
A pharmaceutical composition for treatment of malignancies, in particular a malignant disease which is associated with the development of bone metastases or excessive bone resorption, comprises in combination a bisphosphonates, COX-2 inhibitor and/or a taxol or derivative thereof for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonates, an effective amount of a COX-2 inhibitor and/or and effective amount of a taxol or derivative thereof.
REFERENCES:
patent: WO 00 38730 (2000-07-01), None
patent: WO 01 54688 (2001-08-01), None
Witters et al., “Inhibition of Growth of Human Breast Cancer Cell Lines with the Combination of Zoledronic Acid and a COX-2 Inhibitor”, European Journal of Cancer, vol. 37, No. Suppl. 6, p. 78, (2001).
Urban et al., “Antinociceptive Effects of the Bisphosphonate, Zoledronate, in a Novel Rat Model of Bone Cancer Pain”, Society for Neuroscience Abstracts, vol. 27, No. 1, p. 1326, 31stAnnual Meeting of the Society for Neuroscience, San Diego, Ca, (2001).
McDonnell, et al, “Advances in Cancer Pain Management”, Current Oncology Reports, vol. 2, No. 4, pp. 351-357, (2000).
Gloth, F. M. “Pain Management in Older Adults: Prevention and Treatment”, Journal of the American Geriatrics Society, vol. 49, No. 3, pp. 188-199, (2001).
Soriano et al., “Synergistic Effects of New Chemopreventitive Agents and Conventional Cytotoxic Agents Against Human Lung Cancer Cell Lines”, Cancer Research, American Association for Cancer Research, Baltimore, MD, vol. 59, pp. 6178-6184, (1999).
Oura et al., Databse Cancerlit ′Online!“Effective Alendronate Therapy Against a Bone Metastasis Occurring during Docetaxel Therapy for Breast Cancer-a Case Report”, Database Accession No. 1999430323 & Dan To Kagaku Ryoho, Japanese Journal of Cancer and Chemotherapy! (1999).
Jagdev et al., “The Bisphosphonate, Zoledronic Acid, Induces Apoptosis of Breast Cancer Cells: Evidence of Synergy with Paclitaxel” British Journal of Cancer, London, vol. 8, No. 84, pp. 1126-1134, (2001).
Magnetto et al., “Addictive Antitumor Activities of Taxoids in Combination with the Bisphosphonate Ibandronate Against Invasion and Adhesion of Human Breast Carcinoma Cells to Bone”, International Journal of Cancer, vol. 83, pp. 263-269, (1999).
Green Jonathan
Lipton Allan
Witters Lois Mary
Anderson James D.
Manzari Oona A.
Marschel Ardin H.
Novartis AG
Penn State Research Foundation
LandOfFree
Pharmaceutical composition for use for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for use for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for use for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3906836